Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Overall tophus complete response in patients over time during the randomized controlled trials a

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Variables Pegloticase Pegloticase Placebo
  biweekly monthly  
(n= 62) (n= 64) (n= 29)
Week 13
 Patients with evaluable tophi at visit, n 46 48 25
 CR, n (%) 10 (22) 4 (8) 0
P valueb 0.011 0.292
Week 25
 Patients with evaluable tophi at visit, n 40 39 24
 CR, n (%) 18 (45) 10 (26) 2 (8)
P valueb 0.002 0.110
Final visitc
 Patients with evaluable tophi, n 52 52 27
 CR, n (%) 21 (40) 11 (21) 2 (7)
P valueb 0.002 0.200
  1. aCR, complete response. bPegloticase groups versus placebo for CR. cFinal visit includes data from the patient’s final visit, whenever it occurred, for all evaluable completers and noncompleters.